1 European Society of Gynaecological Oncology ESGO Ovarian Cancer Surgery Guidelines_v2,Guidelines.Esgo.Org/Media/2017/03/ESGO_ovarian_cancer_surgery_brA5_V01-Website.Pdf .
2 RE. Bristow, R. Thomacruz, D. Armstrong and Al., ‘Recurrent Micropapillary Serous Ovarian Carcinoma’, Cancer, 95.4 (2002), 791–800 <https://doi.org/10.1002/cncr.10789> DOI: 10.1200/JCO.2002.20.5.1248.
3 SA. Cannistra, ‘Cancer of the Ovary’, The New England Journal of Medicine, 351.24 (2004), 2519–29 https://doi.org/10.1056/NEJMra041842.
4 T Al Rawahi, A. Lopes, E. Bristow and Al., ‘Surgical Cytoreduction for Recurrent Epithelial Ovarian Cancer’, The Cochrane Database of Systematic Reviews, 2 (2013) https://doi.org/10.1002/14651858.CD008765.pub3.
5 L.C. Hanker, S. Loibl, N. Burchati and Al. ‘The Impact of Second to Sixth Line Therapy on Survival of Relapsed Ovarian Cancer after Primary Taxane/Platinum-Based Therapy’, Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 23.10 (2012) https://doi.org/10.1093/annonc/mds203.
6 E. Pujade-Lauraine, F. Hilpert, B. Weber and Al. ‘Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial’, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 32.13 (2014) https://doi.org/10.1200/JCO.2013.51.4489.
7 J. Prat and FIGO Committee on Gynecologic Oncology, ‘FIGO’s Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication’, Journal of Gynecologic Oncology, 26.2 (2015) https://doi.org/10.3802/jgo.2015.26.2.87.
8 W. Solaß, H. Alexander, G. Nadiradze and Al. ‘Description of a Novel Approach for Intraperitoneal Drug Delivery and the Related Device’, Surgical Endoscopy, 26.7 (2012), 1849–55 https://doi.org/10.1007/s00464-012-2148-0.
9 W. Solaß, A. Herbette, T. Schwartz and Al. , ‘Therapeutic Approach of Human Peritoneal Carcinomatosis with Dbait in Combination with Capnoperitoneum: Proof of Concept’, Surgical Endoscopy, 26.3 (2012) https://doi.org/10.1007/s00464-011-1964-y.
10 A. Blanco, U. Giger-Parbst, W. Solaß and Al. ‘Renal and Hepatic Toxicities after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)’, Annals of Surgical Oncology, 20.7 (2013) https://doi.org/10.1245/s10434-012-2840-2.
11 CB. Tempfer, I. Celik, W. Solaß and Al. , ‘Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Cisplatin and Doxorubicin in Women with Recurrent, Platinum-Resistant Ovarian Cancer: Preliminary Clinical Experience’, Gynecologic Oncology, 132.2 (2014) https://doi.org/10.1016/j.ygyno.2013.11.022.
12 CB. Tempfer, GA. Rezniczek, and Al., ‘Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study’, Anticancer Research, 35.12 (2015) DOI: 10.1055/s-0035-1560004.
13 CB. Tempfer, G Winnekendonk, W. Solaß and Al., ‘Pressurized Intraperitoneal Aerosol Chemotherapy in Women with Recurrent Ovarian Cancer: A Phase 2 Study’, Gynecologic Oncology, 137.2 (2015) https://doi.org/10.1016/j.ygyno.2015.02.009.
14 M. Hübner, F. Grass, H. Texeira-Farinha and Al. ‘Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical Aspects’, European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 43.6 (2017) https://doi.org/10.1016/j.ejso.2017.03.019.
15 K. Odendahl, W. Solaß, C. Demtröder and Al. ‘Quality of Life of Patients with End-Stage Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)’, European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 41.10 (2015) https://doi.org/10.1016/j.ejso.2015.06.001.
16 C. Tempfer, U. Giger-Pabst, Z. Hilal and Al. ‘Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Carcinomatosis: Systematic Review of Clinical and Experimental Evidence with Special Emphasis on Ovarian Cancer’, Archives of Gynecology and Obstetrics, 298.2 (2018) https://doi.org/10.1007/s00404-018-4784-7.
17 N. Bakrin, C. Tempfer, G. Scambia and Al. ‘PIPAC-OV3: A Multicenter, Open-Label, Randomized, Two-Arm Phase III Trial of the Effect on Progression-Free Survival of Cisplatin and Doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. Chemotherapy Alone in Patients with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer’, Pleura and Peritoneum, 3.3 (2018) https://doi.org/10.1515/pp-2018-0114.
18 M. Alyami, M. Hübner, F. Grass and Al. ‘Pressurised Intraperitoneal Aerosol Chemotherapy: Rationale, Evidence, and Potential Indications’, The Lancet. Oncology, 20.7 (2019), e368–77 <https://doi.org/10.1016/S1470-2045(19)30318-3>.
19 M. Nowacki, M. Alyami, L. Villeneuve and Al. ‘Multicenter Comprehensive Methodological and Technical Analysis of 832 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Interventions Performed in 349 Patients for Peritoneal Carcinomatosis Treatment: An International Survey Study’, European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44.7 (2018) https://doi.org/10.1016/j.ejso.2018.02.014.
20 K. K. Karukstis, EH. Thompson, JA. Whiles and Al. ‘Deciphering the Fluorescence Signature of Daunomycin and Doxorubicin’, Biophysical Chemistry, 73.3 (1998) DOI: 10.1200/JCO.2002.20.5.1248.
21 S. L. Zeger, K. Y. Liang, and P. S. Albert, ‘Models for Longitudinal Data: A Generalized Estimating Equation Approach’, Biometrics, 44.4 (1988) https://pubmed.ncbi.nlm.nih.gov/3233245/
22 P. Jacquet and P. H. Sugarbaker, ‘Clinical Research Methodologies in Diagnosis and Staging of Patients with Peritoneal Carcinomatosis’, Cancer Treatment and Research, 82 (1996), 359–74. DOI: 10.1007/978-1-4613-1247-5_23
23 V. Khosrawipour, D. Diaz-Carballo, AH. Acikelli and Al., ‘Cytotoxic Effect of Different Treatment Parameters in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) on the in Vitro Proliferation of Human Colonic Cancer Cells’, World Journal of Surgical Oncology, 15.1 (2017), 43 <https://doi.org/10.1186/s12957-017-1109-4>.
24 V. Khosrawipour, T. Khosrawipour, AJP. Kern and Al., ‘Distribution Pattern and Penetration Depth of Doxorubicin after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a Postmortem Swine Model’, Journal of Cancer Research and Clinical Oncology, 142.11 (2016) https://doi.org/10.1007/s00432-016-2234-0.
25 T. Khosrawipour, J. Schubert, V. Khosrawipour , ‘Particle Stability and Structure on the Peritoneal Surface in Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) Analysed by Electron Microscopy: First Evidence of a New Physical Concept for PIPAC’, Oncology Letters, 17.6 (2019) https://doi.org/10.3892/ol.2019.10162.
26 A. Bellendorf, V. Khosrawipour, T. Khosrawipour and Al. ‘Scintigraphic Peritoneography Reveals a Non-Uniform 99mTc-Pertechnetat Aerosol Distribution Pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Swine Model’, Surgical Endoscopy, 32.1 (2018) https://doi.org/10.1007/s00464-017-5652-4.
27 T. Kakchekeeva, C. Demtröder, NI. Herath and Al. ‘In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (EPIPAC)’, Annals of Surgical Oncology, 2016 https://doi.org/10.1245/s10434-016-5108-4.
28 M. Reymond, C. Demtröder, W. Solaß and Al. ‘Electrostatic Precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (EPIPAC): First in-Human Application’, Pleura and Peritoneum, 1.2 (2016) https://doi.org/10.1515/pp-2016-0005.